Evidence map›Paper›PMID 32112086›Full record

ArticleBiostatistics (Oxford, England)2021

A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics.

Haoyu Zhang, Ni Zhao, Thomas U Ahearn, William Wheeler, Montserrat García-Closas, Nilanjan Chatterjee

Abstract read
In one paragraph

Article in Biostatistics (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. bioRxiv : the preprint server for biology · 2023
    Article
  5. Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  6. Article
  7. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haoyu ZhangDepartment of Biostatistics, Johns Hopkins Bloomberg SPH, 615 N Wolfe St, Baltimore, MD 21205, USA and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850, USA.
Ni ZhaoDepartment of Biostatistics, Johns Hopkins Bloomberg SPH, 615 N Wolfe St, Baltimore, MD 21205, USA.
Thomas U AhearnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850, USA.
William WheelerNational Cancer Institute, Information Management Service, Inc. 11730 Plaza America Dr, Reston, VA 20190, USA.
Montserrat García-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850, USA.
Nilanjan ChatterjeeDepartment of Biostatistics, Johns Hopkins Bloomberg SPH, 615 N Wolfe St, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine SPH, 733 N Broadway, Baltimore, MD 21205, USA and Department of Epidemiology, Johns Hopkins Bloomberg SPH, 615 N Wolfe St, Baltimore, MD 21205, USA.

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Robust Methods for Polygenic Analysis to Inform Disease Etiology and Enhance Risk PredictionR01HG010480 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI CHATTERJEE, NILANJAN · 2019 to 2023
$2.8M
NHGRI NIH HHS R01 HG010480
6 · The paper itself

Abstract

Cancers are routinely classified into subtypes according to various features, including histopathological characteristics and molecular markers. Previous genome-wide association studies have reported heterogeneous associations between loci and cancer subtypes. However, it is not evident what is the optimal modeling strategy for handling correlated tumor features, missing data, and increased degrees-of-freedom in the underlying tests of associations. We propose to test for genetic associations using a mixed-effect two-stage polytomous model score test (MTOP). In the first stage, a standard polytomous model is used to specify all possible subtypes defined by the cross-classification of the tumor characteristics. In the second stage, the subtype-specific case-control odds ratios are specified using a more parsimonious model based on the case-control odds ratio for a baseline subtype, and the case-case parameters associated with tumor markers. Further, to reduce the degrees-of-freedom, we specify case-case parameters for additional exploratory markers using a random-effect model. We use the Expectation-Maximization algorithm to account for missing data on tumor markers. Through simulations across a range of realistic scenarios and data from the Polish Breast Cancer Study (PBCS), we show MTOP outperforms alternative methods for identifying heterogeneous associations between risk loci and tumor subtypes. The proposed methods have been implemented in a user-friendly and high-speed R statistical package called TOP (https://github.com/andrewhaoyu/TOP).

Indexed as

Breast NeoplasmsGenome-Wide Association StudyCase-Control StudiesFemaleHumansOdds RatioRisk FactorsCancer subtypesEM algorithmEtiologic heterogeneityScore testsSusceptibility variantsTwo-stage polytomous model

Identifiers

PMID32112086
PMCPMC8511944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.